CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
The 78th American Academy of Neurology Annual Meeting in Chicago, USA (18-22 April 2026) emphasised connection – sharing knowledge, learning, and growing as a community – with a record number of submitted abstracts and more than 3500 presented.
Patients with cardiovascular (CV) risk factors taking atogepant 60 mg QD for migraine prevention maintain weight loss during 12 months of treatment, according to interim results from an open label extension of the Phase 3 ELEVATE and PROGRESS trials in episodic migraine (EM) and chronic migraine (CM) respectively. In the analysis of 279 patients who …
Read more »Hypertension history appears to modify the blood pressure response to anti-CGRP therapies, with patients with prior hypertension seeming to remain stable or improve and previously normotensive individuals experiencing a modest increase in systolic blood pressure (SBP). These intriguing findings reported by Dr Suresh Kumar and colleagues from the University of Austin, Texas, have emerged from …
Read more »The developmental anti-PACAP antibody, Lu AG09222 (bocunebart), was well tolerated when co-administered with ubrogepant and did not alter ubrogepant pharmacokinetics, results of a Phase 1 study in patients with episodic migraine have shown. In the randomised, double-blind, placebo-controlled study at four US sites, 43 adults aged 18-65 years with ≥2 monthly migraine days, and <15 …
Read more »CGRP reliably provokes typical headache attacks and increases intracranial pressure (ICP) pulse amplitude in patients with idiopathic intracranial hypertension (IIH), without altering mean pressure, providing mechanistic support for CGRP in IIH and justifying evaluation of CGRP blockade in this population. This is the conclusion of Dr Andreas Yiangou, from the University of Birmingham, UK, and …
Read more »Fremanezumab does not reduce migraine days in children and adolescents with chronic migraine (CM) – in contrast to the beneficial effects seen in paediatric studies of episodic migraine (EM). In the Phase 3 SPACE CM trial of fremanezumab in 298 patients with CM (≥ 15 headache days per month), aged 6-17 years, there was no …
Read more »Rimegepant treatment every other day has been shown to improve headache frequency and severity in patients with cluster headache after one week of use. Most patients were very satisfied or somewhat satisfied with rimegepant and wanted to use it again. These findings were reported from a pilot study of 20 patients who met criteria for …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
